Table 1.
Anti-mutant p53 TCR library.
| TCR source (previous reporting) | TP53 mutation | TP53 mutation frequency (%)a | Tumor cell reactivity | HLA restriction | HLA frequency (%)b | Potentially treatable patient (%) |
|---|---|---|---|---|---|---|
| 4141 (10,15); 4196 (12) | R175H | 5.530 | Yes | A*02:01 | 47.40 | 2.621 |
| 4273 (10,15) | R248W | 3.218 | ND | DPB1*02:01 | 27.30 | 0.878 |
| 4259 | Y220C | 1.790 | Yes | A*02:01 | 47.40 | 0.848 |
| 4149 (10,11); 4343 (16) | Y220C | 1.790 | ND | DRB3*02:02 | 32.80 | 0.587 |
| 4285 (10,15) | R175H | 5.530 | ND | DRB1*13:01 | 10.00 | 0.553 |
| 4386 | R273C | 2.259 | ND | DPB1*04:02 | 24.2c | 0.547 |
| 4127 (10,11) | G245S | 1.598 | ND | DRB3*02:02 | 32.80 | 0.524 |
| 4259 (10) | Y220C | 1.790 | Yesd | DRB1*04:01 | 17.30 | 0.310 |
| 4266 (10,15) | R248W | 3.218 | Yes | A*68:01 | 6.38 | 0.205 |
| 4316 | C135Y | 0.426 | ND | DRB1*07:01 | 26.84 | 0.114 |
| 4304 | M237I | 0.426 | ND | DRB1*01:01 | 14.60 | 0.062 |
| 4316 | C135Y | 0.426 | Yes | A*29:02 | 7.06 | 0.030 |
| 4324 | T211I | 0.032 | Yes | C*06:02 | 18.64 | 0.006 |
| 4414 | Y220D | 0.011 | ND | A*02:01 | 47.40 | 0.005 |
| 4114 | C135R | 0.043 | ND | DRB1*11:01 | 10.9 | 0.005 |
| 4350 | L111R | 0.011 | Yes | A*11:01 | 14 | 0.001 |
| 4356 | Q331H | 0.011 | ND | B*40:01 | 11.00 | 0.001 |
| 4350 | L111R | 0.011 | ND | DRB1*08:03 | 0.6 | 0.00006 |
| 4293 | Y236S | 0.011 | ND | DRB3*02:01 | 0.33 | 0.00003 |
| Sum | 7.297 |
Abbreviation: ND, not determined.
aInternational Agency for Research on Cancer (IARC) TP53 Database (R20, July 2019, N = 9,386, colon, rectal, breast, pancreatic, esophageal, and ovarian cancers).
bPhenotype frequency of Caucasian populations in the United States; when the phenotype frequency is not available, twice the allele frequency is reported (http://www.allelefrequencies.net/).
c60% to 80% in Hispanic populations, approximately 20% in African-American and Asian populations.
dTumor cells transduced with DRA1/DRB1*04:01 were recognized while unmodified cells were not.